FGF21 and metabolic dysfunction-associated steatohepatitis: Efruxifermin (formerly AKR-001, AMG 876), the only other FGF21 analog studied in a clinical trial of biopsy-confirmed NASH patients, is a 92 kDa Fc-FGF21fusion protein with a 3–3.5 day half-life (based on intact C-terminal domain of the FGF21 moiety), which is substantially extended relative to the FGF21 analogs described above.